(PRGO) Perrigo - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NYSE (USA) | Market Cap: 1.570m USD | Total Return: -54.6% in 12m
Avg Turnover: 26.9M
EPS Trend: 9.5%
Qual. Beats: 0
Rev. Trend: -97.1%
Qual. Beats: -1
Warnings
Interest Coverage Ratio -7.0 is critical
Altman Z'' -0.65 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Perrigo Company plc is a global provider of over-the-counter (OTC) health and wellness solutions, operating primarily through its Consumer Self-Care Americas and Consumer Self-Care International segments. The company maintains a diverse portfolio covering respiratory, digestive health, nutrition, and skin care categories, marketed under established brands such as Nasonex, Prevacid24HR, and Opill. Beyond its own brands, Perrigo provides contract manufacturing services and distributes products through mass merchandisers, pharmacies, and e-commerce platforms.
The company operates within the consumer healthcare sector, a market characterized by high barriers to entry due to stringent regulatory requirements for manufacturing and labeling. Perrigo’s business model focuses on the store brand strategy, where it produces private-label equivalents of national brands to offer retailers higher margins and consumers lower price points. This positioning allows the company to benefit from defensive consumer spending patterns, as OTC medications are often considered essential goods regardless of economic cycles.
For a deeper look into the companys valuation metrics and historical performance, consider reviewing the detailed data available on ValueRay. Headquartered in Dublin, Ireland, the firm has evolved from its 1887 origins into a specialized pharmaceutical entity focused on self-care accessibility.
- Infant formula supply chain stability impacts Consumer Self-Care Americas segment margins
- Opill retail adoption and market share expansion drive women’s health revenue
- Private label conversion rates during inflationary periods dictate domestic sales growth
- European consumer demand fluctuations influence Consumer Self-Care International segment performance
- Manufacturing cost optimization and portfolio streamlining initiatives determine long-term operating leverage
| Net Income: -1.82b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -0.51 > 1.0 |
| NWC/Revenue: 41.04% < 20% (prev 33.66%; Δ 7.38% < -1%) |
| CFO/TA 0.02 > 3% & CFO 189.4m > Net Income -1.82b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.72 > 1.5 & < 3 |
| Outstanding Shares: last quarter (138.7m) vs 12m ago 0.73% < -2% |
| Gross Margin: 34.17% > 18% (prev 0.36%; Δ 3.38k% > 0.5%) |
| Asset Turnover: 47.10% > 50% (prev 44.42%; Δ 2.68% > 0%) |
| Interest Coverage Ratio: -6.99 > 6 (EBITDA TTM -837.7m / Interest Expense TTM 164.3m) |
| A: 0.21 (Total Current Assets 2.71b - Total Current Liabilities 997.6m) / Total Assets 7.98b |
| B: -0.51 (Retained Earnings -4.08b / Total Assets 7.98b) |
| C: -0.13 (EBIT TTM -1.15b / Avg Total Assets 8.87b) |
| D: 0.46 (Book Value of Equity 2.50b / Total Liabilities 5.48b) |
| Altman-Z'' = -0.65 = B |
| DSRI: 1.06 (Receivables 732.8m/716.8m, Revenue 4.18b/4.34b) |
| GMI: 1.06 (GM 34.17% / 36.38%) |
| AQI: 0.84 (AQ_t 0.53 / AQ_t-1 0.63) |
| SGI: 0.96 (Revenue 4.18b / 4.34b) |
| TATA: -0.25 (NI -1.82b - CFO 189.4m) / TA 7.98b) |
| Beneish M = -3.30 (Cap -4..+1) = AA |
As of May 24, 2026, the stock is trading at USD 11.35 with a total of 1,555,020 shares traded.
Over the past week, the price has changed by +5.75%,
over one month by -5.08%,
over three months by -21.16% and
over the past year by -54.55%.
Perrigo has received a consensus analysts rating of 3.80. Therefore, it is recommended to hold PRGO.
- StrongBuy: 1
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 16.5 | 45.4% |
P/S = 0.3759
P/B = 0.6285
P/EG = 1.1418
Revenue TTM = 4.18b USD
EBIT TTM = -1.15b USD
EBITDA TTM = -837.7m USD
Long Term Debt = 3.62b USD (from longTermDebt, last quarter)
Short Term Debt = 37.5m USD (from shortTermDebt, last quarter)
Debt = 3.98b USD (from shortLongTermDebtTotal, last quarter) + Leases 173.0m
Net Debt = 3.62b USD (calculated: Debt 3.98b - CCE 357.2m)
Enterprise Value = 5.19b USD (1.57b + Debt 3.98b - CCE 357.2m)
Interest Coverage Ratio = -6.99 (Ebit TTM -1.15b / Interest Expense TTM 164.3m)
EV/FCF = 48.20x (Enterprise Value 5.19b / FCF TTM 107.7m)
FCF Yield = 2.07% (FCF TTM 107.7m / Enterprise Value 5.19b)
FCF Margin = 2.58% (FCF TTM 107.7m / Revenue TTM 4.18b)
Net Margin = -43.50% (Net Income TTM -1.82b / Revenue TTM 4.18b)
Gross Margin = 34.17% ((Revenue TTM 4.18b - Cost of Revenue TTM 2.75b) / Revenue TTM)
Gross Margin QoQ = 33.58% (prev 32.64%)
Tobins Q-Ratio = 0.65 (Enterprise Value 5.19b / Total Assets 7.98b)
Interest Expense / Debt = 4.13% (Interest Expense 164.3m / Debt 3.98b)
Taxrate = 21.0% (US default 21%)
NOPAT = -907.2m (EBIT -1.15b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.72 (Total Current Assets 2.71b / Total Current Liabilities 997.6m)
Debt / Equity = 1.59 (Debt 3.98b / totalStockholderEquity, last quarter 2.50b)
Debt / EBITDA = -4.32 (negative EBITDA) (Net Debt 3.62b / EBITDA -837.7m)
Debt / FCF = 33.62 (Net Debt 3.62b / FCF TTM 107.7m)
Total Stockholder Equity = 3.59b (last 4 quarters mean from totalStockholderEquity)
RoA = -20.49% (Net Income -1.82b / Total Assets 7.98b)
RoE = -23.71% (Net Income TTM -1.82b / Total Stockholder Equity 7.66b)
RoCE = -10.18% (EBIT -1.15b / Capital Employed (Equity 7.66b + L.T.Debt 3.62b))
RoIC = -13.15% (negative operating profit) (NOPAT -907.2m / Invested Capital 6.90b)
WACC = 4.72% (E(1.57b)/V(5.55b) * Re(8.40%) + D(3.98b)/V(5.55b) * Rd(4.13%) * (1-Tc(0.21)))
Discount Rate = 8.40% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 80.90 | Cagr: 1.04%
[DCF] Terminal Value 73.10% ; FCFF base≈137.1m ; Y1≈120.2m ; Y5≈97.1m
[DCF] Fair Price = N/A (negative equity: EV 1.56b - Net Debt 3.62b = -2.06b; debt exceeds intrinsic value)
EPS Correlation: 9.54 | EPS CAGR: 0.84% | SUE: 0.56 | # QB: 0
Revenue Correlation: -97.15 | Revenue CAGR: -3.91% | SUE: -2.60 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.36 | Chg30d=-9.47% | Revisions=-43% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.57 | Chg30d=-2.29% | Revisions=-14% | Analysts=4
EPS current Year (2026-12-31): EPS=2.11 | Chg30d=-0.49% | Revisions=-14% | GrowthEPS=-23.4% | GrowthRev=-4.6%
EPS next Year (2027-12-31): EPS=2.36 | Chg30d=-1.05% | Revisions=+0% | GrowthEPS=+12.0% | GrowthRev=+1.0%
[Analyst] Revisions Ratio: -43%